Merck is celebrating its anniversary by conducting 350 charitable activities in around 60 countries

MerckMerck, a leading science and technology ­company, is celebrating its anniversary by conducting 350 charitable activities in around 60 countries. Taking responsibility has always been an integral part of the entrepreneurial approach of Merck and is one of its six values. On the occasion of its 350th anniversary, the company will further intensify its social engagement activities together with its employees.

"We have a long tradition of responsibility, it’s more than just lip service. That's why we want to share the great joy of our anniversary not only with our employees, but also with our local communities," said Walter Galinat, member of the Executive Board of Merck and responsible for the 350th anniversary celebrations. "We take on responsibility for society all over the world. Many of our employees and subsidiaries are involved in this effort, for instance through donations, collaborations with reliable partners and voluntary initiatives," he added.

The activities planned to take place throughout 2018 will focus on health as well as on education and culture. Here, Merck will leverage its 350 years of experience and curiosity, as well as its knowledge and expertise in the areas of health, science and technology. In addition to these efforts, the company also supports a wide array of charitable and environmental initiatives in the communities near its sites and provides disaster relief. The aim is to address challenges facing society, from fighting serious diseases and protecting natural resources to promoting aspiring young scientists.

The projects in the focus area of health are centered around developing local healthcare infrastructure, providing vocational and advanced training to medical staff and raising awareness of health issues. Founded in 2017, for instance, the Merck Foundation supports initiatives to improve the treatment of cancer patients in Africa. And in Guatemala, Merck is working with an organization that provides free healthcare to underprivileged communities and helps people with disabilities.

Within the focus area of education, particular emphasis is placed on sparking young people's interest in science. A prime example is the SPARK volunteer program, under which employees conduct scientific experiments with school children in an effort to arouse their curiosity. A large number of activities are also taking place in Darmstadt, where the company is headquartered. These include an exciting experiment afternoon for school students to mark the tenth anniversary of the Junior Laboratory at the Technical University of Darmstadt. In Indonesia, Merck is supporting the charitable organization Nara Kreatif, with which it is collaborating on environmental and educational projects. These include a school for 300 children in need, at which Merck employees are also volunteering.

Within the focus area of culture, Merck is often engaged in projects that transcend cultural borders, such as a literature initiative in Korea that encourages exchange between Germany and several Asian countries.

About Merck

Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life - from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2016, Merck generated sales of € 15.0 billion in 66 countries.

Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. The company holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

Most Popular Now

Imfinzi is the first immunotherapy to demonstrate …

AstraZeneca and MedImmune, its global biologics research and development arm, have presented data on overall survival (OS) in the Phase III PACIFIC trial of Imfinzi durin...

Sandoz Healthcare Access Challenge #SandozHACk ret…

Sandoz, the Novartis generics and biosimilars division, today announces the launch of the second Sandoz Healthcare Access Challenge (HACk). The #SandozHACk is a global co...

Global survey reveals that physicians need more in…

Results from a new global survey revealed that more than one-third (36%) of the 310 physicians surveyed do not think they have sufficient information required to make inf...

In clinical trials, new antibody therapy controls …

Thanks to improvements in antiretroviral therapy, HIV is now a manageable condition. Yet even the best drugs do not entirely eliminate the virus, which latently lingers i...

Pfizer to award more than $3 million in grants to …

Pfizer Inc. today announced the recipients of the Advancing Science through Pfizer Investigator Research Exchange (ASPIRE) Breast Cancer Research Awards. Four grants tota...

Novartis licenses three novel anti-infective progr…

Novartis announced today that it has entered into a licensing and equity agreement with Boston Pharmaceuticals for the development of three novel anti-infective drug cand...

The Nobel Prize in Physiology or Medicine 2018 was…

Cancer kills millions of people every year and is one of humanity's greatest health challenges. By stimulating the inherent ability of our immune system to attack tumor c...

FDA approves first treatment for advanced form of …

The U.S. Food and Drug Administration today approved Libtayo (cemiplimab-rwlc) injection for intravenous use for the treatment of patients with metastatic cutaneous squam...

FDA approves expanded use of Gardasil 9 to include…

The U.S. Food and Drug Administration approved a supplemental application for Gardasil 9 (Human Papillomavirus (HPV) 9-valent Vaccine, Recombinant) expanding the approved...

DNA islands effective as 'anti-bacterial drones'

Genomic "islands" that evolved from viruses can be converted into "drones" that disable Staphylococcus aureus, bacteria that are often resistant to antibiotics and pose a...

FDA awards 12 grants to fund new clinical trials t…

The U.S. Food and Drug Administration today announced that it has awarded 12 new clinical trial research grants totaling more than $18 million over the next four years to...

Pfizer announces Executive Leadership Team

Pfizer Inc. (NYSE:PFE) today announced its executive team that will report to Albert Bourla, incoming Chief Executive Officer, coincident with the commencement of his new...